Title: SENATE BILL 111
Official Title: SENATE BILL 111
Number of Sections: 1
Source: versions - First - Maryland Medical Assistance Program and Health Insurance - Step Therapy, Fail-First Protocols, and Prior Authorization - Prescription to Treat Serious Mental Illness
Media Type: application/pdf
Strikethrough Detection: 7 sections found

================================================================================

Section 1:
J5, J4, J1 5lr1291
(PRE–FILED)
By: Senator Lam
Requested: October 21, 2024
Introduced and read first time: January 8, 2025
Assigned to: Finance
A BILL ENTITLED
1 AN ACT concerning
2 Maryland Medical Assistance Program and Health Insurance – Step Therapy,
3 Fail–First Protocols, and Prior Authorization – Prescription to Treat Serious
4 Mental Illness
5 FOR the purpose of prohibiting the Maryland Medical Assistance Program and certain
6 insurers, nonprofit health service plans, health maintenance organizations, and
7 managed care organizations from applying a prior authorization requirement, step
8 therapy protocol, or fail–first protocol for prescription drugs used to treat certain
9 mental illnesses of certain insureds and enrollees; and generally relating to coverage
10 of prescription drugs to treat serious mental illness.
11 BY adding to
12 Article – Health – General
13 Section 15–102.3(m) and 15–157
14 Annotated Code of Maryland
15 (2023 Replacement Volume and 2024 Supplement)
16 BY repealing and reenacting, with amendments,
17 Article – Insurance
18 Section 15–142
19 Annotated Code of Maryland
20 (2017 Replacement Volume and 2024 Supplement)
21 BY adding to
22 Article – Insurance
23 Section 15–851.1
24 Annotated Code of Maryland
25 (2017 Replacement Volume and 2024 Supplement)
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from exist in g l aw . *sb0111*
2 SENATE BILL 111
1 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
2 That the Laws of Maryland read as follows:
3 Article – Health – General
4 15–102.3.
5 (M) THE PROVISIONS OF §§ 15–142(E)(2) AND 15–851.1 OF THE INSURANCE
6 ARTICLE APPLY TO MANAGED CARE ORGANIZATIONS.
7 15–157.
8 (A) IN THIS SECTION, “STEP THERAPY OR FAIL–FIRST PROTOCOL” HAS THE
9 MEANING STATED IN § 15–142 OF THE INSURANCE ARTICLE.
10 (B) EXCEPT AS REQUIRED UNDER 42 U.S.C. § 1396A, BEGINNING JULY 1,
11 2025, THE PROGRAM MAY NOT APPLY A PRIOR AUTHORIZATION REQUIREMENT FOR
12 A PRESCRIPTION DRUG USED TO TREAT AN ADULT ENROLLEE’S DIAGNOSIS OF:
13 (1) BIPOLAR DISORDER;
14 (2) SCHIZOPHRENIA;
15 (3) MAJOR DEPRESSION;
16 (4) POST–TRAUMATIC STRESS DISORDER; OR
17 (5) A MEDICATION–INDUCED MOVEMENT DISORDER ASSOCIATED
18 WITH THE TREATMENT OF A SERIOUS MENTAL ILLNESS.
19 (C) BEGINNING JULY 1, 2025, THE PROGRAM MAY NOT APPLY A STEP
20 THERAPY OR FAIL–FIRST PROTOCOL FOR A PRESCRIPTION DRUG USED TO TREAT AN
21 ENROLLEE’S DIAGNOSIS OF:
22 (1) BIPOLAR DISORDER;
23 (2) SCHIZOPHRENIA;
24 (3) MAJOR DEPRESSION;
25 (4) POST–TRAUMATIC STRESS DISORDER; OR
26 (5) A MEDICATION–INDUCED MOVEMENT DISORDER ASSOCIATED
27 WITH THE TREATMENT OF A SERIOUS MENTAL ILLNESS.
SENATE BILL 111 3
1 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read
2 as follows:
3 Article – Insurance
4 15–142.
5 (a) (1) In this section the following words have the meanings indicated.
6 (2) “Step therapy drug” means a prescription drug or sequence of
7 prescription drugs required to be used under a step therapy or fail–first protocol.
8 (3) “Step therapy exception request” means a request to override a step
9 therapy or fail–first protocol.
10 (4) (i) “Step therapy or fail–first protocol” means a protocol established
11 by an insurer, a nonprofit health service plan, or a health maintenance organization that
12 requires a prescription drug or sequence of prescription drugs to be used by an insured or
13 an enrollee before a prescription drug ordered by a prescriber for the insured or the enrollee
14 is covered.
15 (ii) “Step therapy or fail–first protocol” includes a protocol that
16 meets the definition under subparagraph (i) of this paragraph regardless of the name, label,
17 or terminology used by the insurer, nonprofit health service plan, or health maintenance
18 organization to identify the protocol.
19 (5) “Supporting medical information” means:
20 (i) a paid claim from an entity subject to this section for an insured
21 or an enrollee;
22 (ii) a pharmacy record that documents that a prescription has been
23 filled and delivered to an insured or an enrollee, or a representative of an insured or an
24 enrollee; or
25 (iii) other information mutually agreed on by an entity subject to this
26 section and the prescriber of an insured or an enrollee.
27 (b) (1) This section applies to:
28 (i) insurers and nonprofit health service plans that provide hospital,
29 medical, or surgical benefits to individuals or groups on an expense–incurred basis under
30 health insurance policies or contracts that are issued or delivered in the State; and
4 SENATE BILL 111
1 (ii) health maintenance organizations that provide hospital,
2 medical, or surgical benefits to individuals or groups under contracts that are issued or
3 delivered in the State.
4 (2) An insurer, a nonprofit health service plan, or a health maintenance
5 organization that provides coverage for prescription drugs through a pharmacy benefits
6 manager is subject to the requirements of this section.
7 (c) An entity subject to this section may not impose a step therapy or fail–first
8 protocol on an insured or an enrollee if:
9 (1) the step therapy drug has not been approved by the U.S. Food and Drug
10 Administration for the medical condition being treated; or
11 (2) a prescriber provides supporting medical information to the entity that
12 a prescription drug covered by the entity:
13 (i) was ordered by a prescriber for the insured or enrollee within the
14 past 180 days; and
15 (ii) based on the professional judgment of the prescriber, was
16 effective in treating the insured’s or enrollee’s disease or medical condition.
17 (d) Subsection (c) of this section may not be construed to require coverage for a
18 prescription drug that is not:
19 (1) covered by the policy or contract of an entity subject to this section; or
20 (2) otherwise required by law to be covered.
21 (e) An entity subject to this section may not impose a step therapy or fail–first
22 protocol on an insured or an enrollee for a prescription drug approved by the U.S. Food and
23 Drug Administration if:
24 (1) (I) the prescription drug is used to treat the insured’s or enrollee’s
25 stage four advanced metastatic cancer; and
26 [(2)] (II) use of the prescription drug is:
27 [(i)] 1. consistent with the U.S. Food and Drug
28 Administration–approved indication or the National Comprehensive Cancer Network
29 Drugs & Biologics Compendium indication for the treatment of stage four advanced
30 metastatic cancer; and
31 [(ii)] 2. supported by peer–reviewed medical literature; OR
SENATE BILL 111 5
1 (2) THE PRESCRIPTION DRUG IS USED TO TREAT THE INSURED’S OR
2 ENROLLEE’S DIAGNOSIS OF:
3 (I) BIPOLAR DISORDER;
4 (II) SCHIZOPHRENIA;
5 (III) MAJOR DEPRESSION;
6 (IV) POST–TRAUMATIC STRESS DISORDER; OR
7 (V) A MEDICATION–INDUCED MOVEMENT DISORDER
8 ASSOCIATED WITH THE TREATMENT OF A SERIOUS MENTAL ILLNESS.
9 (f) (1) An entity subject to this section shall establish a process for requesting
10 an exception to a step therapy or fail–first protocol that is:
11 (i) clearly described, including the specific information and
12 documentation, if needed, that must be submitted by the prescriber to be considered a
13 complete step therapy exception request;
14 (ii) easily accessible to the prescriber; and
15 (iii) posted on the entity’s website.
16 (2) A step therapy exception request shall be granted if, based on the
17 professional judgment of the prescriber and any information and documentation required
18 under paragraph (1)(i) of this subsection:
19 (i) the step therapy drug is contraindicated or will likely cause an
20 adverse reaction to the insured or enrollee;
21 (ii) the step therapy drug is expected to be ineffective based on the
22 known clinical characteristics of the insured or enrollee and the known characteristics of
23 the prescription drug regimen;
24 (iii) the insured or enrollee is stable on a prescription drug prescribed
25 for the medical condition under consideration while covered under the policy or contract of
26 the entity or under a previous source of coverage; or
27 (iv) while covered under the policy or contract of the entity or a
28 previous source of coverage, the insured or enrollee has tried a prescription drug that:
29 1. is in the same pharmacologic class or has the same
30 mechanism of action as the step therapy drug; and
6 SENATE BILL 111
1 2. was discontinued by the prescriber due to lack of efficacy
2 or effectiveness, diminished effect, or an adverse event.
3 (3) On granting a step therapy exception request, an entity subject to this
4 section shall authorize coverage for the prescription drug ordered by the prescriber for an
5 insured or enrollee.
6 (4) An enrollee or insured may appeal a step therapy exception request
7 denial in accordance with Subtitle 10A or Subtitle 10B of this title.
8 (5) This subsection may not be construed to:
9 (i) prevent:
10 1. an entity subject to this section from requiring an insured
11 or enrollee to try an AB–rated generic equivalent or interchangeable biological product
12 before providing coverage for the equivalent branded prescription drug; or
13 2. a health care provider from prescribing a prescription
14 drug that is determined to be medically appropriate; or
15 (ii) require an entity subject to this section to provide coverage for a
16 prescription drug that is not covered by a policy or contract of the entity.
17 (6) An entity subject to this section may use an existing step therapy
18 exception process that satisfies the requirements under this subsection.
19 15–851.1.
20 (A) (1) THIS SECTION APPLIES TO:
21 (I) INSURERS AND NONPROFIT HEALTH SERVICE PLANS THAT
22 PROVIDE COVERAGE FOR PRESCRIPTION DRUGS UNDER INDIVIDUAL, GROUP, OR
23 BLANKET HEALTH INSURANCE POLICIES OR CONTRACTS THAT ARE ISSUED OR
24 DELIVERED IN THE STATE; AND
25 (II) HEALTH MAINTENANCE ORGANIZATIONS THAT PROVIDE
26 COVERAGE FOR PRESCRIPTION DRUGS UNDER INDIVIDUAL OR GROUP CONTRACTS
27 THAT ARE ISSUED OR DELIVERED IN THE STATE.
28 (2) AN INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH
29 MAINTENANCE ORGANIZATION THAT PROVIDES COVERAGE FOR PRESCRIPTION
30 DRUGS THROUGH A PHARMACY BENEFITS MANAGER IS SUBJECT TO THE
31 REQUIREMENTS OF THIS SECTION.
SENATE BILL 111 7
1 (B) EXCEPT AS REQUIRED UNDER 42 U.S.C. § 1396A, AN ENTITY SUBJECT
2 TO THIS SECTION MAY NOT APPLY A PRIOR AUTHORIZATION REQUIREMENT FOR A
3 PRESCRIPTION DRUG USED TO TREAT AN ADULT INSURED’S OR ENROLLEE’S
4 DIAGNOSIS OF:
5 (1) BIPOLAR DISORDER;
6 (2) SCHIZOPHRENIA;
7 (3) MAJOR DEPRESSION;
8 (4) POST–TRAUMATIC STRESS DISORDER; OR
9 (5) A MEDICATION–INDUCED MOVEMENT DISORDER ASSOCIATED
10 WITH THE TREATMENT OF A SERIOUS MENTAL ILLNESS.
11 SECTION 3. AND BE IT FURTHER ENACTED, That:
12 (a) On or before January 31, 2027, and each January 1 thereafter through 2031,
13 the Maryland Department of Health shall report to the Department of Legislative Services
14 on any cost increase to the Maryland Medical Assistance Program from the immediately
15 preceding fiscal year that results from the implementation of Section 1 of this Act.
16 (b) On or before April 30 of the year in which a report is submitted under
17 subsection (a) of this section, the Department of Legislative Services shall determine, based
18 on the report, whether the implementation of Section 1 of this Act resulted in a cost increase
19 to the Maryland Medical Assistance Program of more than $2,000,000 from the
20 immediately preceding fiscal year.
21 (c) If the Department of Legislative Services determines that the implementation
22 of Section 1 of this Act resulted in a cost increase to the Maryland Medical Assistance
23 Program of more than $2,000,000 from the immediately preceding fiscal year, with no
24 further action required by the General Assembly, at the end of April 30 of the year the
25 determination is made, Section 1 of this Act shall be abrogated and of no further force and
26 effect.
27 SECTION 4. AND BE IT FURTHER ENACTED, That Section 2 of this Act shall
28 apply to all policies, contracts, and health benefit plans issued, delivered, or renewed in the
29 State on or after January 1, 2026.
30 SECTION 5. AND BE IT FURTHER ENACTED, That Section 2 of this Act shall take
31 effect January 1, 2026.
32 SECTION 6. AND BE IT FURTHER ENACTED, That, except as provided in Section
33 5 of this Act, this Act shall take effect July 1, 2025.
[DELETED: :CA      5 (   A M F M F i n h s p h m o a m t m o B  A S  A  ( B  A S  A  ( B  A S  A  (]
[DELETED:  S   S T A 1 ) T§§1())11H  E    N.() I,“–NN SLFL     N R12IA.() E42U.§16,J1X    A  U , RES: ( B; ( S; ( M; ( P–;TTR  ( AMNI M D A ) BJ1,2,E U   T R M N A A SLFES: ( B; ( S; ( M; ( P–;TTR  ( AMNI M D A]
[DELETED: S 3  S a A 1  ( ( I   ( “ t d m a p d o s o p   ( “ t   ( ( “ b r a i    ( “ t o f p i a p t m o o   ( “    ( a o    ( a f e    ( o s  ( ( T    ( i m h]
[DELETED:  S     ( h m o t p h m d   ( A o m  ( A p   ( t A   ( a a    ( w p    ( b o t p j o t p w e  ( S p   ( c   ( o  ( A p D   ( ttt) s   ()  u](    () c w t U F a D]1 A i o t N C C N D & B C i f t t o s f a m    ()  s]2.;]
[DELETED: S 5 ( DSES:  () ;B  () ;IS  () ;IMN  () –;VPTTR   () A MNI M D .  ( ( A a    ( c d i t s i a d c    ( e    ( p   ( A s t e r s b g i b o t p u    ( t a    ( t k t    ( t f t    ( w c u t p o c o t e o a p     1 i i t s p c o h t s m]
[DELETED:  S      2 w o   ( O s i   ( A d   ( T    ( p     1 a o b     2 a h c p f p a p d    ( r p   ( A e s t t s m u a e s t e() ( T:H  ()IL P  H I P O C T A I O TE ;  ()IH M O T P T. ( A,R N  O T P C F P T A P B M I S T T]
[DELETED: S 7() E42U.§16X    A  D U T T A A IDS O EES ( ; ( ; ( ;N ( –;TTR  (  MNI M D A  S  ( O t o p  ( O o b A 3 o t y i w a r i s u s o t t M M A P o m t $ f t i  ( I o P o m t $ f t i p f y w n f d e  S a S  S e  S 5]


================================================================================

Raw Text:
SENATE BILL 111
J5, J4, J1 5lr1291
(PRE–FILED)
By: Senator Lam
Requested: October 21, 2024
Introduced and read first time: January 8, 2025
Assigned to: Finance
A BILL ENTITLED
1 AN ACT concerning
2 Maryland Medical Assistance Program and Health Insurance – Step Therapy,
3 Fail–First Protocols, and Prior Authorization – Prescription to Treat Serious
4 Mental Illness
5 FOR the purpose of prohibiting the Maryland Medical Assistance Program and certain
6 insurers, nonprofit health service plans, health maintenance organizations, and
7 managed care organizations from applying a prior authorization requirement, step
8 therapy protocol, or fail–first protocol for prescription drugs used to treat certain
9 mental illnesses of certain insureds and enrollees; and generally relating to coverage
10 of prescription drugs to treat serious mental illness.
11 BY adding to
12 Article – Health – General
13 Section 15–102.3(m) and 15–157
14 Annotated Code of Maryland
15 (2023 Replacement Volume and 2024 Supplement)
16 BY repealing and reenacting, with amendments,
17 Article – Insurance
18 Section 15–142
19 Annotated Code of Maryland
20 (2017 Replacement Volume and 2024 Supplement)
21 BY adding to
22 Article – Insurance
23 Section 15–851.1
24 Annotated Code of Maryland
25 (2017 Replacement Volume and 2024 Supplement)
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from exist in g l aw . *sb0111*

2 SENATE BILL 111
1 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
2 That the Laws of Maryland read as follows:
3 Article – Health – General
4 15–102.3.
5 (M) THE PROVISIONS OF §§ 15–142(E)(2) AND 15–851.1 OF THE INSURANCE
6 ARTICLE APPLY TO MANAGED CARE ORGANIZATIONS.
7 15–157.
8 (A) IN THIS SECTION, “STEP THERAPY OR FAIL–FIRST PROTOCOL” HAS THE
9 MEANING STATED IN § 15–142 OF THE INSURANCE ARTICLE.
10 (B) EXCEPT AS REQUIRED UNDER 42 U.S.C. § 1396A, BEGINNING JULY 1,
11 2025, THE PROGRAM MAY NOT APPLY A PRIOR AUTHORIZATION REQUIREMENT FOR
12 A PRESCRIPTION DRUG USED TO TREAT AN ADULT ENROLLEE’S DIAGNOSIS OF:
13 (1) BIPOLAR DISORDER;
14 (2) SCHIZOPHRENIA;
15 (3) MAJOR DEPRESSION;
16 (4) POST–TRAUMATIC STRESS DISORDER; OR
17 (5) A MEDICATION–INDUCED MOVEMENT DISORDER ASSOCIATED
18 WITH THE TREATMENT OF A SERIOUS MENTAL ILLNESS.
19 (C) BEGINNING JULY 1, 2025, THE PROGRAM MAY NOT APPLY A STEP
20 THERAPY OR FAIL–FIRST PROTOCOL FOR A PRESCRIPTION DRUG USED TO TREAT AN
21 ENROLLEE’S DIAGNOSIS OF:
22 (1) BIPOLAR DISORDER;
23 (2) SCHIZOPHRENIA;
24 (3) MAJOR DEPRESSION;
25 (4) POST–TRAUMATIC STRESS DISORDER; OR
26 (5) A MEDICATION–INDUCED MOVEMENT DISORDER ASSOCIATED
27 WITH THE TREATMENT OF A SERIOUS MENTAL ILLNESS.

SENATE BILL 111 3
1 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read
2 as follows:
3 Article – Insurance
4 15–142.
5 (a) (1) In this section the following words have the meanings indicated.
6 (2) “Step therapy drug” means a prescription drug or sequence of
7 prescription drugs required to be used under a step therapy or fail–first protocol.
8 (3) “Step therapy exception request” means a request to override a step
9 therapy or fail–first protocol.
10 (4) (i) “Step therapy or fail–first protocol” means a protocol established
11 by an insurer, a nonprofit health service plan, or a health maintenance organization that
12 requires a prescription drug or sequence of prescription drugs to be used by an insured or
13 an enrollee before a prescription drug ordered by a prescriber for the insured or the enrollee
14 is covered.
15 (ii) “Step therapy or fail–first protocol” includes a protocol that
16 meets the definition under subparagraph (i) of this paragraph regardless of the name, label,
17 or terminology used by the insurer, nonprofit health service plan, or health maintenance
18 organization to identify the protocol.
19 (5) “Supporting medical information” means:
20 (i) a paid claim from an entity subject to this section for an insured
21 or an enrollee;
22 (ii) a pharmacy record that documents that a prescription has been
23 filled and delivered to an insured or an enrollee, or a representative of an insured or an
24 enrollee; or
25 (iii) other information mutually agreed on by an entity subject to this
26 section and the prescriber of an insured or an enrollee.
27 (b) (1) This section applies to:
28 (i) insurers and nonprofit health service plans that provide hospital,
29 medical, or surgical benefits to individuals or groups on an expense–incurred basis under
30 health insurance policies or contracts that are issued or delivered in the State; and

4 SENATE BILL 111
1 (ii) health maintenance organizations that provide hospital,
2 medical, or surgical benefits to individuals or groups under contracts that are issued or
3 delivered in the State.
4 (2) An insurer, a nonprofit health service plan, or a health maintenance
5 organization that provides coverage for prescription drugs through a pharmacy benefits
6 manager is subject to the requirements of this section.
7 (c) An entity subject to this section may not impose a step therapy or fail–first
8 protocol on an insured or an enrollee if:
9 (1) the step therapy drug has not been approved by the U.S. Food and Drug
10 Administration for the medical condition being treated; or
11 (2) a prescriber provides supporting medical information to the entity that
12 a prescription drug covered by the entity:
13 (i) was ordered by a prescriber for the insured or enrollee within the
14 past 180 days; and
15 (ii) based on the professional judgment of the prescriber, was
16 effective in treating the insured’s or enrollee’s disease or medical condition.
17 (d) Subsection (c) of this section may not be construed to require coverage for a
18 prescription drug that is not:
19 (1) covered by the policy or contract of an entity subject to this section; or
20 (2) otherwise required by law to be covered.
21 (e) An entity subject to this section may not impose a step therapy or fail–first
22 protocol on an insured or an enrollee for a prescription drug approved by the U.S. Food and
23 Drug Administration if:
24 (1) (I) the prescription drug is used to treat the insured’s or enrollee’s
25 stage four advanced metastatic cancer; and
26 [(2)] (II) use of the prescription drug is:
27 [(i)] 1. consistent with the U.S. Food and Drug
28 Administration–approved indication or the National Comprehensive Cancer Network
29 Drugs & Biologics Compendium indication for the treatment of stage four advanced
30 metastatic cancer; and
31 [(ii)] 2. supported by peer–reviewed medical literature; OR

SENATE BILL 111 5
1 (2) THE PRESCRIPTION DRUG IS USED TO TREAT THE INSURED’S OR
2 ENROLLEE’S DIAGNOSIS OF:
3 (I) BIPOLAR DISORDER;
4 (II) SCHIZOPHRENIA;
5 (III) MAJOR DEPRESSION;
6 (IV) POST–TRAUMATIC STRESS DISORDER; OR
7 (V) A MEDICATION–INDUCED MOVEMENT DISORDER
8 ASSOCIATED WITH THE TREATMENT OF A SERIOUS MENTAL ILLNESS.
9 (f) (1) An entity subject to this section shall establish a process for requesting
10 an exception to a step therapy or fail–first protocol that is:
11 (i) clearly described, including the specific information and
12 documentation, if needed, that must be submitted by the prescriber to be considered a
13 complete step therapy exception request;
14 (ii) easily accessible to the prescriber; and
15 (iii) posted on the entity’s website.
16 (2) A step therapy exception request shall be granted if, based on the
17 professional judgment of the prescriber and any information and documentation required
18 under paragraph (1)(i) of this subsection:
19 (i) the step therapy drug is contraindicated or will likely cause an
20 adverse reaction to the insured or enrollee;
21 (ii) the step therapy drug is expected to be ineffective based on the
22 known clinical characteristics of the insured or enrollee and the known characteristics of
23 the prescription drug regimen;
24 (iii) the insured or enrollee is stable on a prescription drug prescribed
25 for the medical condition under consideration while covered under the policy or contract of
26 the entity or under a previous source of coverage; or
27 (iv) while covered under the policy or contract of the entity or a
28 previous source of coverage, the insured or enrollee has tried a prescription drug that:
29 1. is in the same pharmacologic class or has the same
30 mechanism of action as the step therapy drug; and

6 SENATE BILL 111
1 2. was discontinued by the prescriber due to lack of efficacy
2 or effectiveness, diminished effect, or an adverse event.
3 (3) On granting a step therapy exception request, an entity subject to this
4 section shall authorize coverage for the prescription drug ordered by the prescriber for an
5 insured or enrollee.
6 (4) An enrollee or insured may appeal a step therapy exception request
7 denial in accordance with Subtitle 10A or Subtitle 10B of this title.
8 (5) This subsection may not be construed to:
9 (i) prevent:
10 1. an entity subject to this section from requiring an insured
11 or enrollee to try an AB–rated generic equivalent or interchangeable biological product
12 before providing coverage for the equivalent branded prescription drug; or
13 2. a health care provider from prescribing a prescription
14 drug that is determined to be medically appropriate; or
15 (ii) require an entity subject to this section to provide coverage for a
16 prescription drug that is not covered by a policy or contract of the entity.
17 (6) An entity subject to this section may use an existing step therapy
18 exception process that satisfies the requirements under this subsection.
19 15–851.1.
20 (A) (1) THIS SECTION APPLIES TO:
21 (I) INSURERS AND NONPROFIT HEALTH SERVICE PLANS THAT
22 PROVIDE COVERAGE FOR PRESCRIPTION DRUGS UNDER INDIVIDUAL, GROUP, OR
23 BLANKET HEALTH INSURANCE POLICIES OR CONTRACTS THAT ARE ISSUED OR
24 DELIVERED IN THE STATE; AND
25 (II) HEALTH MAINTENANCE ORGANIZATIONS THAT PROVIDE
26 COVERAGE FOR PRESCRIPTION DRUGS UNDER INDIVIDUAL OR GROUP CONTRACTS
27 THAT ARE ISSUED OR DELIVERED IN THE STATE.
28 (2) AN INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH
29 MAINTENANCE ORGANIZATION THAT PROVIDES COVERAGE FOR PRESCRIPTION
30 DRUGS THROUGH A PHARMACY BENEFITS MANAGER IS SUBJECT TO THE
31 REQUIREMENTS OF THIS SECTION.

SENATE BILL 111 7
1 (B) EXCEPT AS REQUIRED UNDER 42 U.S.C. § 1396A, AN ENTITY SUBJECT
2 TO THIS SECTION MAY NOT APPLY A PRIOR AUTHORIZATION REQUIREMENT FOR A
3 PRESCRIPTION DRUG USED TO TREAT AN ADULT INSURED’S OR ENROLLEE’S
4 DIAGNOSIS OF:
5 (1) BIPOLAR DISORDER;
6 (2) SCHIZOPHRENIA;
7 (3) MAJOR DEPRESSION;
8 (4) POST–TRAUMATIC STRESS DISORDER; OR
9 (5) A MEDICATION–INDUCED MOVEMENT DISORDER ASSOCIATED
10 WITH THE TREATMENT OF A SERIOUS MENTAL ILLNESS.
11 SECTION 3. AND BE IT FURTHER ENACTED, That:
12 (a) On or before January 31, 2027, and each January 1 thereafter through 2031,
13 the Maryland Department of Health shall report to the Department of Legislative Services
14 on any cost increase to the Maryland Medical Assistance Program from the immediately
15 preceding fiscal year that results from the implementation of Section 1 of this Act.
16 (b) On or before April 30 of the year in which a report is submitted under
17 subsection (a) of this section, the Department of Legislative Services shall determine, based
18 on the report, whether the implementation of Section 1 of this Act resulted in a cost increase
19 to the Maryland Medical Assistance Program of more than $2,000,000 from the
20 immediately preceding fiscal year.
21 (c) If the Department of Legislative Services determines that the implementation
22 of Section 1 of this Act resulted in a cost increase to the Maryland Medical Assistance
23 Program of more than $2,000,000 from the immediately preceding fiscal year, with no
24 further action required by the General Assembly, at the end of April 30 of the year the
25 determination is made, Section 1 of this Act shall be abrogated and of no further force and
26 effect.
27 SECTION 4. AND BE IT FURTHER ENACTED, That Section 2 of this Act shall
28 apply to all policies, contracts, and health benefit plans issued, delivered, or renewed in the
29 State on or after January 1, 2026.
30 SECTION 5. AND BE IT FURTHER ENACTED, That Section 2 of this Act shall take
31 effect January 1, 2026.
32 SECTION 6. AND BE IT FURTHER ENACTED, That, except as provided in Section
33 5 of this Act, this Act shall take effect July 1, 2025.

[DELETED: :CA      5 (   A M F M F i n h s p h m o a m t m o B  A S  A  ( B  A S  A  ( B  A S  A  (]
[DELETED:  S   S T A 1 ) T§§1())11H  E    N.() I,“–NN SLFL     N R12IA.() E42U.§16,J1X    A  U , RES: ( B; ( S; ( M; ( P–;TTR  ( AMNI M D A ) BJ1,2,E U   T R M N A A SLFES: ( B; ( S; ( M; ( P–;TTR  ( AMNI M D A]
[DELETED: S 3  S a A 1  ( ( I   ( “ t d m a p d o s o p   ( “ t   ( ( “ b r a i    ( “ t o f p i a p t m o o   ( “    ( a o    ( a f e    ( o s  ( ( T    ( i m h]
[DELETED:  S     ( h m o t p h m d   ( A o m  ( A p   ( t A   ( a a    ( w p    ( b o t p j o t p w e  ( S p   ( c   ( o  ( A p D   ( ttt) s   ()  u](    () c w t U F a D]1 A i o t N C C N D & B C i f t t o s f a m    ()  s]2.;]
[DELETED: S 5 ( DSES:  () ;B  () ;IS  () ;IMN  () –;VPTTR   () A MNI M D .  ( ( A a    ( c d i t s i a d c    ( e    ( p   ( A s t e r s b g i b o t p u    ( t a    ( t k t    ( t f t    ( w c u t p o c o t e o a p     1 i i t s p c o h t s m]
[DELETED:  S      2 w o   ( O s i   ( A d   ( T    ( p     1 a o b     2 a h c p f p a p d    ( r p   ( A e s t t s m u a e s t e() ( T:H  ()IL P  H I P O C T A I O TE ;  ()IH M O T P T. ( A,R N  O T P C F P T A P B M I S T T]
[DELETED: S 7() E42U.§16X    A  D U T T A A IDS O EES ( ; ( ; ( ;N ( –;TTR  (  MNI M D A  S  ( O t o p  ( O o b A 3 o t y i w a r i s u s o t t M M A P o m t $ f t i  ( I o P o m t $ f t i p f y w n f d e  S a S  S e  S 5]